NCT01991210终止2 期
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 95
- 试验地点
- 36
- 主要终点
- Progression-free Survival According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
研究概览
简要总结
This randomized, multicenter, open-label study will evaluate the safety and efficacy of DNIB0600A (RO5541081) in comparison with PLD in participants with PROC, primary peritoneal cancer or fallopian tube cancer. Participants will be randomized to receive either DNIB0600A 2.4 milligrams per kilogram (mg/kg) intravenously (IV) every 3 weeks or PLD 40 milligrams per meter-squared (mg/m^2) IV every 4 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Histologically documented epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- •Advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed or relapsed during or within 6 months after the most recent treatment with a platinum-containing chemotherapy regimen and for whom PLD is appropriate therapy
- •No more than 1 prior cytotoxic chemotherapy regimens for the treatment of PROC and not more than 2 total regimens (defined as any therapy [approved or investigational] with intent to treat the ovarian cancer)
- •Adequate hematologic, renal and liver function
- •Willing and able to perform a patient-reported outcome (PRO) survey (including the possibility of using an electronic PRO device)
- •For women of childbearing potential, agreement to use 1 highly effective form of contraception as defined by protocol through the course of study treatment and for 6 months after the last dose of study treatment
排除标准
- •Primary platinum-refractory disease defined as disease progression during or within 2 months of a first-line, platinum-containing chemotherapy regimen
- •Anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy, within 4 weeks prior to Day 1
- •Palliative radiation within 2 weeks prior to Day 1
- •Prior anthracycline therapy, including prior treatment with PLD (for example, Doxil®, Caelyx®, or Lipodox®) in any setting (for example, in combination with carboplatin or as a single agent)
- •Prior treatment with NaPi2b or SCL34A2 targeted therapy
- •Major surgical procedure within 4 weeks prior to Day 1
- •Current Grade greater than (>) 1 toxicity (except alopecia and anorexia) from prior therapy or Grade >1 neuropathy from any cause
- •Left ventricular ejection fraction defined by multigated acquisition (MUGA)/echocardiogram below the institutional lower limit of normal
- •Evidence of significant, uncontrolled, concomitant disease that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or significant pulmonary disease
- •Known active infection, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (within 4 weeks prior to Cycle 1, Day 1)
- •Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
- •Presence of positive test results for hepatitis B or hepatitis C as detailed in the protocol
- •Known history of HIV seropositive status
- •Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix, squamous carcinoma of the skin, adequately controlled limited basal cell skin cancer, or synchronous primary endometrial cancer or prior primary endometrial cancer
- •Untreated or active central nervous system metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
- •Pregnancy or breastfeeding
- •Known history of NaPi2b deficiency (for example, congenital alveolar microlithiasis or testicular microlithiasis)
- •History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
- •Metabolic dysfunction, physical examination finding, or clinical laboratory find giving reasonable suspicion of a disease or condition that contraindicated use of an investigational drug or may render the participant at high risk from treatment complications
研究组 & 干预措施
DNIB0600A
Experimental
DNIB0600A will be administered on Day 1 of each cycle (1 cycle = 21 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
干预措施: DNIB0600A (Drug)
PLD
Active Comparator
PLD will be administered on Day 1 of each cycle (1 cycle = 28 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
干预措施: PLD (Drug)
结局指标
主要结局
Progression-free Survival According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
时间窗: From baseline up to disease progression or death within 30 days of last study drug administration (overall up to approximately 2.5 years)
次要结局
- Maximum Concentration (Cmax) of DNIB0600A(Pre-DNIB0600A infusion, 30 minutes post infusion (infusion length=90 minutes) on Day 1 of each Cycle (1cycle=21 days) (overall up to approximately 2.5 years); Day 8 of Cycle 1; Day 15 of Cycles 1-4)
- Clearance (CL) of DNIB0600A(Pre-DNIB0600A infusion, 30 minutes post infusion (infusion length=90 minutes) on Day 1 of each Cycle (1cycle=21 days) (overall up to approximately 2.5 years); Day 8 of Cycle 1; Day 15 of Cycles 1-4)
- Elimination Half-life (t1/2) of DNIB0600A(Pre-DNIB0600A infusion, 30 minutes post infusion (infusion length=90 minutes) on Day 1 of each Cycle (1cycle=21 days) (overall up to approximately 2.5 years); Day 8 of Cycle 1; Day 15 of Cycles 1-4)
- Volume of Distribution at Steady State (Vss) of DNIB0600A(Pre-DNIB0600A infusion, 30 minutes post infusion (infusion length=90 minutes) on Day 1 of each Cycle (1cycle=21 days) (overall up to approximately 2.5 years); Day 8 of Cycle 1; Day 15 of Cycles 1-4)
- Percentage of Participants With Anti-therapeutic Antibodies (ATAs) Against DNIB0600A(Pre-DNIB0600A infusion on Day 1 of Cycles 1-4 (1cycle=21 days), at approximately 15-30 days after last infusion administration (overall up to approximately 2.5 years))
- Percentage of Participants With Adverse Events (AEs)(From baseline up to 30 days of last study drug administration (overall up to approximately 2.5 years))
- Overall Survival (OS)(From baseline up to death from any cause (overall up to approximately 2.5 years))
- Percentage of Participants With Objective Response According to RECIST v1.1(From baseline up to 30 days of last study drug administration (overall up to approximately 2.5 years))
- Duration of Objective Response(From occurrence of a documented objective response until relapse or death from any cause (overall up to approximately 2.5 years))
- Area Under the Concentration-time Curve (AUC) of DNIB0600A(Pre-DNIB0600A infusion, 30 minutes post infusion (infusion length=90 minutes) on Day 1 of each Cycle (1cycle=21 days) (overall up to approximately 2.5 years); Day 8 of Cycle 1; Day 15 of Cycles 1-4)
研究者
研究点 (36)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung CancerNon-Squamous Non-Small Cell Lung CancerNCT01995188Genentech, Inc.41
Unknown
2 期
Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF MutationLung Cancer MetastaticBRAF V600ECancerNCT03543306Asan Medical Center27
已完成
1 期
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian CancerNon-Small Cell Lung Cancer, Ovarian CancerNCT01363947Genentech, Inc.87
招募中
1 期
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsNon-Small Cell Lung Cancer (NSCLC)NCT05271916Shanghai Chest Hospital140
招募中
1 期
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLCNon-small Cell Lung Cancer (NSCLC)NCT06754930Suzhou Suncadia Biopharmaceuticals Co., Ltd.400